NCT02502994Unknown1 期
Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients With Recurrence of Castration Resistant Prostate Cancer
Norio Nonomura1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- DLT (Dose Limiting Toxicity)
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of a single injection of GEN0101 in patients with recurrence of castration resistant prostate cancer.
The subjects receive GEN0101 injection 4 times per two weeks (1st intratumoral injection and followed subcutaneous injection) and two weeks of observation as one cycle treatment period. Each subject receive two cycle treatment period.
Low dose group: 30,000m NAU per injection of GEN0101 High dose group: 60,000m NAU per injection of GEN0101 Each group included minimal 3 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients providing a written informed consent by voluntary agreement.
- •Age 20 =< and =<85 years old at the time of informed consent
- •Have a diagnosis of malignant tumor as confirmed by histology or cytology.
- •Have a diagnosis of recurrence of castration resistant prostate cancer and meet the following condition
- •Inapplicable to the standard treatment, ineffective through the criteria of the Prostate Cancer Clinical Trials Working Group (PCWG2) or refuse the standard treatment
- •More than 6 week between the end date of the standard treatment and the registration date when the standard treatment has been ineffective
- •Serum PSA <100 ng/mL at the screening visit
- •Expected survival period is more than 8 weeks after planned start date of investigational product
- •ECOG Performance Status 0 or 1
- •Have an injectable intraprostatic lesion confirmed by histologic examination
- •The marrow function, liver function and the kidney function must be kept as follows at the screening visit (1) leukocyte >= 3,000/mcL (2) neutrophil >=1,500/mcL (3) platelet >=75,000/mcL (4) hemoglobin >=8.0 g/dL. (5) AST =<100 IU/L (6) ALT =<100 IU/L (7) total bilirubin =<2.5 mg/dL (8) serum creatinine =<2.5 mg/dL
排除标准
- •Have multiple brain metastases
- •Positive result of the prick test of GEN0101
- •Have serious complications such as uncontrolled active infection
- •Received systemic chemotherapy, radiotherapy or immunotherapy within 6 weeks before the planned registration date However the hormone therapy except for the estramustine, enzalutamide and abiraterone, bisphosphonate and anti-RANKL antigen antibody is are not included in the systemic chemotherapy.
- •Received another investigational medical product within 4 weeks before the informed concent
- •Had a history of malignancy other than prostate cancer, except for the relapse-free and metastasis-free for more than 5 years after the last treatment at the registration
- •Have an active autoimmune disease
- •Receiving systemic administration of glucocorticosteroid which restrains immunity response, except for the administration for a long period (over 6 months) of the low dose (equivalent to under 10 mg/day oral prednisolone).
- •Had a history of the autologous or homogeneous organ or tissue transplantation (Receiving immunosuppressive medication)
- •PT(%) less than 10% of the lower limit of normal or APTT more than 1.5 times of the upper limit of normal of local reference range at the screening visit
- •Positive result of the hepatitis B surface antigen, HCV antibody or HIV test at the screening visit
- •Inappropriate to be enrolled in this study judged by the investigators
研究组 & 干预措施
Intervention
Other
Single arm of the castration resistant prostate cancer
干预措施: GEN0101 (Drug)
结局指标
主要结局
DLT (Dose Limiting Toxicity)
时间窗: 8 weeks
To determine the appropriate dosing strategy for GEN0101 for castration resistant prostate cancer
次要结局
- Change from baseline in induction of antitumor immunity (NK cell activity, IL-6 and IFN-gamma) at Cycle1, Week 2 and Week 4 and at Cycle2, Week 2 and Week 4.(8 weeks)
- Change from baseline in tumor marker (PSA: Prostate Specific Antigen, NSE: Neuron-specific enolase, CEA: Carcinoembryonic Antigen, and CA19-9: Carbohydrate Antigen19-9) at Cycle 1, Week 4 and at Cycle 2, Week 4.(8 weeks)
- Change from baseline in prostate histological evaluation at Cycle2, Week2.(8 weeks)
- Number of participants with tumor shrinkage according to the RECIST.(8 weeks)
研究者
Norio Nonomura
Professor
Osaka University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of OA-235i in Subjects With Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNonalcoholic Fatty LiverNCT05680233Oasis Pharmaceuticals, LLC24
终止
1 期
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapySquamous Cell Carcinoma of Head and NeckUrothelial CarcinomaSmall-cell Lung CancerCutaneous Squamous Cell CarcinomaAnal Squamous Cell CarcinomaNon-small Cell Lung CancerMerkel Cell CarcinomaRenal Cell CarcinomaMelanomaNCT04596033Genocea Biosciences, Inc.49
招募中
1 期
Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A(CMT1A) (Phase 1b: Open-label, Dose-escalation, Single-center; Phase 2a: Randomized, Double-blind, Placebo-controlled, Multicenter)Charcot-Marie-Tooth Disease Type 1ANCT06328712ENCell27
已完成
1 期
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent PorphyriaAcute Intermittent PorphyriaNCT02082860Digna Biotech S.L.8
Unknown
1 期
Study of Safety and Biomarker Efficacy of TS23 in Healthy VolunteerThrombosisCerebral IschemiaMyocardial InfarctionVenous ThrombosisPulmonary EmbolismNCT03001544Translational Sciences, Inc.24